Upstream sourcing is not anonymized, and lot files stay live in the COA archive so reviewers can inspect what they need before signing off the order
Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone
Below are some of the key areas we proudly serve throughout greater San Diego
What the Phase 2 Trial Arms Looked Like The table below records what was administered in that trial and the least-squares mean changes reported at 48 weeks a record of past research, not a protocol
Pharmacol Ther 100:235255 Hayes MR, Schmidt HD (2016) GLP-1 influences food and drug reward
Researchers are also exploring its application in treating obesity independently of diabetes, pointing toward broader therapeutic implications
